All In Biotech

Drug Trial Radar · NCT02788747

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Last checked: Nov 20, 2026Latest source record: May 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Jun 2016

Primary completion

Sep 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Stealth BioTherapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).

Conditions

  • Heart Failure

Interventions

  • 4 mg elamipretideDrug

    Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days

  • 40 mg elamipretideDrug

    Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days

  • PlaceboDrug

    Subcutaneous injection of placebo administered once daily for 28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Left Ventricular End Systolic Volume (ml)Time frame: Baseline to Week 4

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • A.O. Papa Giovanni XXIII Cardiologia 1, Torre 5

    Bergamo, Italy

  • A.O. Spedali Civili di Brescia Cardiologia

    Brescia, Italy

  • Azienda Ospedaliera Brotzu Cardiologia

    Cagliari, Italy

  • Centro Cardiologico Monzino U.O. Scompenso, Cardiologia Clinica e Cardiologia Riabilitativa

    Milan, Italy

  • Ospedale Niguarda Ca' Granda SC Cardiologia 2

    Milan, Italy

  • Cardiologia clinica, Unità dello Scompenso e Terapia intensive Reparto Carlo Magno, Faggi Policlinico di Monza

    Monza, Italy

  • Dip. Cardiotoracovascolare: Cardiologia Fondazione IRCCS Policlinico San Matteo Pad. Nuovo Ospedale "DEA" Degenza: PIANO +3 Ambulatori: P.T. e P+3

    Pavia, Italy

  • Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica

    Pisa, Italy

  • Deventer Hospital, Department of Cardiology

    Deventer, Netherlands

  • University Medical Centre Groningen

    Groningen, Netherlands

  • Anthonius Ziekenhuis, Cardiology Department

    Sneek, Netherlands

  • Elisabeth Twee Steden Hospital (ETZ), Department of Cardiology

    Tilburg, Netherlands

  • Gelre Ziekenhuis Zutphen, Department of Cardiology

    Zutphen, Netherlands

  • Ninewells Hospital and Medical School

    Dundee, United Kingdom

  • William Harvey Heart Centre CRC, (Barts Health NHS Trust)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.